Botulinum Toxin Provides New Treatment Option
|
|
For patients with an uncommon condition causing a swollen appearance of the lower face, treatment with botulinum toxin type A (Botox) provides an effective alternative to plastic surgery, according to a study in the November Journal of Craniofacial Surgery. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Dr. Gianpaolo Tartaro and colleagues of Seconda Università degli Studi di Napoli, Italy, report on the use of botulinum toxin type A to treat patients with masseteric muscle hypertrophy (MMH). Patients with MMH have painless enlargement of the masseter (cheek) muscles, causing a swollen or “square-faced” appearance. The cause of MMH is unknown. In the past, the only treatment option was plastic surgery to remove part of the masseter muscle and/or jawbone.
Botulinum Toxin Provides New Treatment Option
Dr. Tartaro and colleagues used botulinum toxin type A to treat MMH in five patients—three women and two men, aged 46 to 56 years. Known by the brand name Botox, botulinum toxin is commonly used for cosmetic plastic surgery, including treatment of forehead wrinkles. Injected into muscles, the toxin blocks nerve transmission, causing those muscles to relax.
In the MMH patients, botulinum toxin was injected directly into the swollen masseter muscle. An average of 20 days later, the patients had reduced swelling and improvement in the contour of the lower face. In one patient, treatment had to be repeated on one side of the face. None of the patients had any complications, and all were highly satisfied with their results.
Botulinum toxin has become a useful treatment for a wide range of problems affecting the facial muscles—not just for “cosmetic” issues like frown lines and wrinkles, but also for problems of eye alignment (strabismus), facial muscle spasms, and others.
The new study adds to previous reports showing that botulinum toxin injection is a safe and effective alternative to plastic surgery for patients with lower facial deformity caused by MMH. Dr. Tartaro and his coauthors conclude, “[T]his study suggests that the use of botulinum toxin type A…can be established as a simple, predictable, alternative facial contouring procedure.”
About The Journal of Craniofacial Surgery
The Journal of Craniofacial Surgery serves as a forum of communication for all those involved in craniofacial and maxillofacial surgery. Coverage ranges from practical aspects of craniofacial surgery to the basic science that underlies surgical practice. Affiliates include 14 major specialty societies around the world, including the American Association of Pediatric Plastic Surgeons, the American Academy of Pediatrics Section of Pediatric Plastic Surgery, the American Society of Craniofacial Surgeons, the American Society of Maxillofacial Surgeons, the Argentine Society of Plastic Surgery Section of Pediatric Plastic Surgery, the Asian Pacific Craniofacial Association, the Association of Military Plastic Surgeons of the U.S., the Brazilian Society of Craniofacial Surgeons, the European Society of Craniofacial Surgery, the International Society of Craniofacial Surgery, the Japanese Society of Craniofacial Surgery, the Korean Society of Craniofacial Surgery, the Thai Cleft and Craniofacial Association, and the World Craniofacial Foundation.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company with annual revenues (2007) of €3.4 billion ($4.8 billion), maintains operations in over 33 countries across Europe, North America, and Asia Pacific and employs approximately 19,500 people worldwide. Visit http://www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
Source: Wolters Kluwer Health: Lippincott Williams & Wilkins
Print Version
Tell-a-Friend comments powered by Disqus
